Health Care

Mike Tremblay September 12, 2019

Market access is wrapped in the politics of health The attention politicians and stakeholders pay to healthcare and its challenges is a keen driver of the ease or difficulty companies experience with drug regulation and market access and has implications through the development process to discovery. How this manifests itself, in part depends on a […]

Mike Tremblay July 6, 2019

To some extent Academic Health Science Centres [AHSCs] are caught between the research push and market pull. If they prioritise technology transfer, they opt for a research push approach that emphasises the availability of technologies or innovations for market-based actors based on potential commercial application. While the university mission within an AHSC will emphasise the […]

Mike Tremblay July 4, 2019

It is not unreasonable to have concerns about the cost of medicines. Drug costs are usually influenced by government policies on pricing and reimbursement of medicines themselves. These range from simple discount seeking to more complex approaches such as conditional approvals, and value-based pricing (perhaps a subject for another posting). These can achieve a measure […]

Mike Tremblay July 3, 2019

Discussions on health literacy are increasing as healthcare providers, clinicians, payers and patients consider what this means for healthcare. Having been involved in launching the world’s first digital interactive health channel in the UK in 2000, one thing I learned is not to assume that everyone is alike or has common interests. Healthcare systems are […]

Mike Tremblay June 4, 2019

Pain is, well, a pain. It is the one thing we all have direct experience of, and can communicate to others, but which defies direct clinical measurement. We are left with subjective measures of pain, such as the ‘oucher’ scale or similar. While it is frustrating not to have a direct way to measure pain, […]

Mike Tremblay March 6, 2019

The relevance of value in establishing the positioning of medicines is the new normal for pharmaceutical marketing. Pharmaceutical companies have customers who are highly constrained by whether healthcare system funding is sustainable long term. Remember, payers think epidemiologically and in multiple years of costed care so industry needs to assess how that can be understood […]

Mike Tremblay July 5, 2018

From the UK Guardian: private healthcare providers. The research on comparative performance of for profit and not for profit healthcare providers is well developed, so it is surprising to see such a weak quality assessment about private providers in the NHS. The NHS is a very difficult customer for a number of reasons, primarily the glass […]